Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
What will happen during the trial?
PRIMARY OBJECTIVE:
I. To provide a blinded reference set of cancer versus (vs.) non-cancer blood samples that will be used to validate assays for inclusion in a prospective clinical trial focused on utility of blood-based multi-cancer early detection.
SECONDARY OBJECTIVES:
I. Evaluate test performance at the time of initial cancer diagnosis by tumor type.
II. Evaluate test performance at the time of initial cancer diagnosis by clinical stage.
OUTLINE:
Participants complete a questionnaire at baseline. Participants undergo collection of blood samples at registration and at 12 months after registration. Patients with a cancer diagnosis may undergo collection of tissue samples at registration and 12 months after registration.
After completion of study, participants are followed up at 1 year.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 2,000 patients (estimated)
- Sponsors
- Alliance for Clinical Trials in Oncology
- Collaborators
- National Cancer Institute (NCI)
- Trial Type
- Observational
- Last Update
- 4 months ago
- SparkCures ID
- 1808
- NCT Identifier
- NCT05334069
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.